Heart and Vessels

, Volume 27, Issue 3, pp 280–286 | Cite as

Steady-state B-type natriuretic peptide levels in patients with atrial fibrillation of various clinical backgrounds

  • Tsuneaki SadanagaEmail author
  • Hideo Mitamura
  • Shun Kohsaka
  • Satoshi Ogawa
Original Article


B-type natriuretic peptide level is increased in patients with atrial fibrillation. The aim of the present study was to present the distribution of steady-state B-type natriuretic peptide levels of various clinical backgrounds and to elucidate the usefulness of measuring them in patients with atrial fibrillation. B-type natriuretic peptide was measured in stable conditions in patients with atrial fibrillation (74 ± 10 y/o, n = 473). The average B-type natriuretic peptide level was 161 ± 202 (median 101) pg/ml. Multiple regression analysis showed that age, left ventricular ejection fraction, left atrial diameter, structural heart disease, chronic atrial fibrillation, and heart failure symptoms were independently associated with elevated B-type natriuretic peptide levels. However, in chronic atrial fibrillation patients without structural heart disease, B-type natriuretic peptide levels did not differ between those with and without heart failure symptoms. Notably, B-type natriuretic peptide levels were high (≥150 pg/ml) in 41% of asymptomatic chronic atrial fibrillation without structural heart disease. Steady-state B-type natriuretic peptide levels of various clinical backgrounds were presented. Contributions of BNP elevation by clinical variables were somewhat different in different population. B-type natriuretic peptide was elevated in substantial percentage of asymptomatic chronic atrial fibrillation even without structural heart disease.


B-type natriuretic peptide Atrial fibrillation Heart failure Structural heart disease 


  1. 1.
    Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, Gardetto N, Wanner E, Maisel AS (2002) Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recordings. Circulation 105:595–601PubMedCrossRefGoogle Scholar
  2. 2.
    Lukowicz T, Fischera M, Hense HW, Dfring A, Stritzked J, Rieggera G, Schunkert H, Luchner A (2005) BNP as a marker of diastolic dysfunction in the general population: importance of left ventricular hypertrophy. Eur J Heart Fail 7:525–531PubMedCrossRefGoogle Scholar
  3. 3.
    Seki S, Tsurusaki T, Kasai T, Taniguchi I, Mochizuki S, Yoshimura M (2008) Clinical significance of B-type natriuretic peptide in the assessment of untreated hypertension. Circ J 72:770–777PubMedCrossRefGoogle Scholar
  4. 4.
    Silvet H, Young-Xu Y, Walleigh D, Ravid S (2003) Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92:1124–1127PubMedCrossRefGoogle Scholar
  5. 5.
    Kim BJ, Hwang SJ, Sung KC, Kim BS, Kang JH, Lee MH, Park JR (2007) Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. Int J Cardiol 118:145–150PubMedCrossRefGoogle Scholar
  6. 6.
    Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167PubMedCrossRefGoogle Scholar
  7. 7.
    Knudsen CW, Omland T, Clopton P, Westheim A, Wu AH, Duc P, McCord J, Nowak RM, Hollander JE, Storrow AB, Abraham WT, McCullough PA, Maisel A (2005) Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol 46:838–844PubMedCrossRefGoogle Scholar
  8. 8.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMedCrossRefGoogle Scholar
  9. 9.
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the Modification of Diet in Renal Disease Study Group (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130:461–470PubMedCrossRefGoogle Scholar
  10. 10.
    Gwechenberger M, Huelsmann M, Graf S, Berger R, Bonderman D, Stanek B, Rauscha F, Pacher R (2004) Natriuretic peptides and the prevalence of congestive heart failure in patients with pacemakers. Eur J Clin Invest 34:811–817PubMedCrossRefGoogle Scholar
  11. 11.
    Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB (2000) Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 35:1256–1262PubMedCrossRefGoogle Scholar
  12. 12.
    Doust J, Lehman R, Glasziou P (2006) The role of BNP testing in heart failure. Am Fam Physician 74:1893–1898PubMedGoogle Scholar
  13. 13.
    Tsuchida K, Tanabe K (2004) Influence of paroxysmal atrial fibrillation attack on brain natriuretic peptide secretion. J Cardiol 44:1–11PubMedGoogle Scholar
  14. 14.
    Jourdain P, Bellorini M, Funck F, Fulla Y, Guillard N, Loiret J, Thebault B, Sadeg N, Desnos M (2002) Short-term effects of sinus rhythm restoration in patients with lone atrial fibrillation: a hormonal study. Eur J Heart Fail 4:263–267PubMedCrossRefGoogle Scholar
  15. 15.
    Li J, Wang L (2006) B-type natriuretic peptide levels in patients with paroxysmal lone atrial fibrillation. Heart Vessels 21:137–140PubMedCrossRefGoogle Scholar
  16. 16.
    Bakowski D, Wozakowska-Kaplon B, Opolski G (2009) The influence of left ventricle diastolic function on natriuretic peptides levels in patients with atrial fibrillation. Pacing Clin Electrophysiol 32:745–752PubMedCrossRefGoogle Scholar
  17. 17.
    Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348:2007–2018PubMedCrossRefGoogle Scholar
  18. 18.
    Engelmann MD, Niemann L, Kanstrup IL, Skagen K, Godtfredsen J (2005) Natriuretic peptide response to dynamic exercise in patients with atrial fibrillation. Int J Cardiol 105:31–39PubMedCrossRefGoogle Scholar
  19. 19.
    Wu AH, Smith A, Wieczorek S, Mather JF, Duncan B, White CM, McGill C, Katten D, Heller G (2003) Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92:628–631PubMedCrossRefGoogle Scholar
  20. 20.
    Vogeser M, Jacob K (2001) B-type natriuretic peptide (BNP)—validation of an immediate response assay. Clin Lab 47:29–33PubMedGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Tsuneaki Sadanaga
    • 1
    Email author
  • Hideo Mitamura
    • 2
  • Shun Kohsaka
    • 3
  • Satoshi Ogawa
    • 4
  1. 1.Division of CardiologyUeki HospitalKumamotoJapan
  2. 2.Saiseikai Central HospitalTokyoJapan
  3. 3.Division of Cardiology, Department of MedicineKeio University School of MedicineTokyoJapan
  4. 4.International University of Health and Welfare, Mita HospitalTokyoJapan

Personalised recommendations